Bernard Zinman
Mount Sinai Hospital
3 papers in the Anchorcite directory, published between 2015 and 2019, cited 26,918 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 3 papers
- Diabetes, Cardiovascular Risks, and Lipoproteins · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Acute Kidney Injury Research · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
Frequent co-authors
- Christoph Wanner · 1 paper
- John M. Lachin · 1 paper
- DAVID H. FITCHETT · 1 paper
- Erich Bluhmki · 1 paper
- Stefan Hantel · 1 paper
- Michaela Mattheus · 1 paper
- Theresa Devins · 1 paper
- Odd Erik Johansen · 1 paper
Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine · 2015 · 12,596 citations
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to…
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2016 · 7,900 citations
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular…
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…
Metadata from OpenAlex (CC0).